- Home
- NBTX vs MNPR Comparison
NBTX vs MNPR Comparison
Compare NBTX & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- MNPR
- Stock Information
- Founded
- NBTX 2003
- MNPR 2014
- Country
- NBTX France
- MNPR United States
- Employees
- NBTX N/A
- MNPR N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- MNPR Health Care
- Exchange
- NBTX Nasdaq
- MNPR Nasdaq
- Market Cap
- NBTX 211.9M
- MNPR 248.8M
- IPO Year
- NBTX 2020
- MNPR 2019
- Fundamental
- Price
- NBTX $9.70
- MNPR $49.22
- Analyst Decision
- NBTX Strong Buy
- MNPR Strong Buy
- Analyst Count
- NBTX 1
- MNPR 11
- Target Price
- NBTX $8.00
- MNPR $68.60
- AVG Volume (30 Days)
- NBTX 15.1K
- MNPR 38.9K
- Earning Date
- NBTX 09-18-2025
- MNPR 11-07-2025
- Dividend Yield
- NBTX N/A
- MNPR N/A
- EPS Growth
- NBTX N/A
- MNPR N/A
- EPS
- NBTX N/A
- MNPR N/A
- Revenue
- NBTX N/A
- MNPR N/A
- Revenue This Year
- NBTX N/A
- MNPR N/A
- Revenue Next Year
- NBTX $74.67
- MNPR N/A
- P/E Ratio
- NBTX N/A
- MNPR N/A
- Revenue Growth
- NBTX N/A
- MNPR N/A
- 52 Week Low
- NBTX $2.76
- MNPR $3.17
- 52 Week High
- NBTX $10.59
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- NBTX 62.98
- MNPR 67.11
- Support Level
- NBTX $8.03
- MNPR $42.51
- Resistance Level
- NBTX $9.14
- MNPR $45.78
- Average True Range (ATR)
- NBTX 0.56
- MNPR 3.42
- MACD
- NBTX -0.02
- MNPR 1.71
- Stochastic Oscillator
- NBTX 68.67
- MNPR 97.14
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.